VEGFR Inhibitors
| Cat. No. | Product Name / Activity |
|---|---|
| 5318 | AEE 788 |
| Potent VEGFR and EGFR inhibitor | |
| 2617 | AG 879 |
| VEGFR-2 inhibitor | |
| 4274 | AP 24534 |
| Potent multi-kinase and pan-Bcr-Abl inhibitor | |
| 4350 | Axitinib |
| Potent VEGFR-1, -2 and -3 inhibitor | |
| 6069 | BMS 605541 |
| Potent VEGFR-2 inhibitor | |
| 4471 | DMH4 |
| Selective VEGFR-2 inhibitor | |
| 3882 | (E)-FeCP-oxindole |
| Selective VEGFR-2 inhibitor | |
| 3883 | (Z)-FeCP-oxindole |
| Selective VEGFR-2 inhibitor | |
| 6056 | GSK 1363089 |
| Potent inhibitor of MET, VEGFR2, Ron and AXL | |
| 2542 | Ki 8751 |
| Potent, selective VEGFR-2 inhibitor | |
| 7049 | Nintedanib |
| Potent VEGFR, PDGFR and FGFR inhibitor | |
| 6015 | RAF 265 |
| VEGFR-2 and Raf kinase inhibitor | |
| 6814 | Sorafenib |
| VEGFR-2 and VEGFR-3 inhibitor; also inhibits Raf-1, PDGFR-β, Flt-3 and cKIT | |
| 1459 | SU 4312 |
| Potent inhibitor of VEGFR tyrosine kinase | |
| 3300 | SU 5402 |
| Potent VEGFR and FGFR inhibitor | |
| 3037 | SU 5416 |
| VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3 | |
| 3335 | SU 6668 |
| VEGFR, PDGFR and FGFR inhibitor | |
| 3768 | Sunitinib malate |
| Potent VEGFR, PDGFRβ and KIT inhibitor | |
| 3909 | Toceranib |
| Potent PDGFR and VEGFR inhibitor | |
| 5680 | Vatalanib succinate |
| Potent VEGFR inhibitor; also aromatase inhibitor | |
| 5422 | XL 184 |
| Potent VEGFR inhibitor; also inhibits other RTKs | |
| 2499 | ZM 306416 hydrochloride |
| Inhibitor of VEGF receptor tyrosine kinase | |
| 2475 | ZM 323881 hydrochloride |
| Potent, selective inhibitor of VEGFR-2 |
Cancer Research Product Guide
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyDownload PDFKinases Product Listing
Our Kinase listing highlights over 400 products for kinase research.
Request copyDownload PDFAngiogenesis in Cancer Life Science Poster
Taken from the Cancer Product Guide Edition 3
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDF